

Clinical trials of antithrombotics for stable angina in all type of patient

TrialResults-center www.trialresultscenter.org

1 aspirin

Trial	Treatments	Patients	Trials design and methods
aspirin vs placebo			
SAPAT , 1992 n=1009/1026 follow-up: 50 months	aspirin 75 mg daily versus placebo	patients with stable chronic angina pectoris	Parallel groups double blind Sweden

References

SAPAT, 1992:

Juul-Miller S, Edvardsson N, Jahnmatz B, Rosn A, Srensen S, Omblus R Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421-5 [[1360557](#)]

2 clopidogrel

Trial	Treatments	Patients	Trials design and methods
clopidogrel vs aspirin			
ASCET [NCT00222261] n=498/503 follow-up:	clopidogrel 75 mg once daily for two years versus Aspirin 160 mg once daily for two years	patients with documented coronary heart disease and treated with aspirin	Parallel groups open

References

ASCET, :

3 dipyridamol

Trial	Treatments	Patients	Trials design and methods
dipyridamol vs control			

continued...

Trial	Treatments	Patients	Trials design and methods
Atlanta (Sbar) , 1967 n=30/30 follow-up: 6 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Wirecki , 1967 n=28/28 follow-up: 7 months	dipyridamole 150mg daily versus placebo	patients with angina pectoris	parallel groups double blind
Becker , 1967 n=14/13 follow-up: 5 months	dipyridamole 225mg daily versus placebo	-	parallel groups double-blind
dipyridamol vs placebo			
Kinsella , 1962 n=13/13 follow-up: 0.5 months	dipyridamole 37.5 mg and 100mg daily versus placebo	-	parallel groups double-blind
Leiberman , 1964 n=19/19 follow-up: >3 months	dipyridamole 100mg daily versus placebo	-	parallel groups double blind
Zion , 1961 n=14/14 follow-up: 0.5 months	Dipyridamole 37.5mg versus placebo	patients with angina pectoris	cross-over double-blind
Dewar , 1961 n=17/17 follow-up: 0.5 months	Dipyridamole 100mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Neumann , 1964 n=20/16 follow-up: 1.5 months	dipyridamole 150mg daily versus placebo	elderly with precordial pain	parallel groups double-blind
Foulds , 1960 n=24/24 follow-up: 1 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double-blind
Igloe , 1970 n=26/22 follow-up: 2-7 months	Dipyridamole 200mg daily versus placebo	patients with angina pectoris	parallel groups double blind

References

Atlanta (Sbar), 1967:

Sbar S, Schlant RC Dipyridamole in the treatment of angina pectoris. A double-blind evaluation. JAMA 1967;201:865-7 [5340622]

Wirecki, 1967:

Wirecki M Treatment of angina pectoris with dipyridamole: a long-term double blind study. J Chronic Dis 1967;20:139-45 [5336520]

Becker, 1967:

Becker MC. Angina pectoris: A double blind study with dipyridamole Journal of the Newark Beth Israel Hospital 1967;18:88-94

Kinsella, 1962:

KINSELLA D, TROUP W, MCGREGOR M Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51 [14456202]

Leiberman, 1964:

LEIBERMAN A, GUGLIEMELLI S PERSANTIN- A DOUBLE BLIND STUDY. Angiology 1964;15:290-2 [14170587]

Zion, 1961:

ZION MM, BRADLOW BA A controlled clinical trial of 'persantin' (R A 8) in angina pectoris. S Afr Med J 1961;35:11-3 [13788617]

Dewar, 1961:

DEWAR HA, HORLER AR A clinical trial of Persantin and Crodimyl in the treatment of angina of effort. Scott Med J 1961;6:149-52 [13722387]

Neumann, 1964:

NEUMANN M, LUISADA AA EFFECT OF RAPID AND SLOW-ACTING "CORONARY" DRUGS ON PRECORDIAL PAIN OF THE AGED. Am J Med Sci 1964;247:156-63 [14124704]

Foulds, 1960:

FOULDS T, MACKINNON J Controlled double-blind trial of "persantin" in treatment of angina pectoris. Br Med J 1960;2:835 [13824151]

Igloe, 1970:

Igloe MC Treatment of angina pectoris with dipyridamole: a double-blind study. J Am Geriatr Soc 1970;18:233-41 [4984849]

4 oral platelet GP IIb/IIIa receptor inhibitor

Trial	Treatments	Patients	Trials design and methods
roxifiban vs placebo			
Murphy , 2003 n=120 follow-up: 30 days	roxifiban 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, or 2.5 mg/day for up to 30 days versus placebo	patients with stable coronary artery disease	Parallel groups double blind

References

Murphy, 2003:

Murphy J, Wright RS, Gussak I, Williams B, Daly RN, Cain VA, Pieniaszek HJ, Sy SK, Ebling W, Simonson K, Wilcox RA, Kopecky SL The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease. Am J Cardiovasc Drugs 2003;3:101-12 [14727937]

5 ticlopidine

Trial	Treatments	Patients	Trials design and methods
ticlopidine vs placebo			
Berglund , 1985 n=21/17 follow-up: 2m	ticlopidine 500 mg daily versus placebo	middle-aged men with stable incapacitating angina pectoris	parallel groups double blind

References

Berglund, 1985:

Berglund U, von Schenck H, Wallentin L Effects of ticlopidine of platelet function in men with stable angina pectoris. Thromb Haemost 1985;54:808-12 [3911481]

6 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.